Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 ​vaccine in healthy adults aged 50 to ...
April 1 (Reuters) - The weight-loss drug market is surging, with biotech firms racing to corner a share in a sector dominated by Novo Nordisk and Eli Lilly. Analysts forecast the industry will ...
Industry growth is driven by demand for cost-effective generics and emerging market access Paclitaxel Injection Market Paclitaxel Injection Market Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The ...
Pfizer held a close to 12% stake in ViiV Healthcare, a London-based pharmaceutical venture specialising in HIV and AIDS ...
Looking further ahead, this market is poised to expand to $10.82 billion by 2030, achieving a CAGR of 5.1%. Key factor ...
The Japanese health ministry is set to begin regular vaccinations for respiratory syncytial virus, or RSV, which can cause pneumonia in infants, on Wednesday, the start of fiscal 2026. Infants in Japa ...
10d
Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever
The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...
China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said The treatment, also known as ecnoglutide, is a once-weekly ...
The company has not disclosed pricing or a launch timeline. The approval also comes as Novo Nordisk's Wegovy nears patent expiry later this month, potentially paving the way for lower-cost copycat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results